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Abstract The urinary steroid profile is constituted by
anabolic androgenic steroids, including testosterone and
its relatives, that are extensively metabolized into phase II
sulfated or glucuronidated steroids. The use of liquid
chromatography coupled to mass spectrometry (LC-MS)
is an issue for the direct analysis of conjugated steroids,
which can be used as urinary markers of exogenous steroid
administration in doping analysis, without hydrolysis of the
conjugated moiety. In this study, a sensitive and selective
ultra high-pressure liquid chromatography coupled to
quadrupole time-of-flight mass spectrometer (UHPLC-
QTOF-MS) method was developed to quantify major
urinary metabolites simultaneously after testosterone intake.
The sample preparation of the urine (1 mL) was performed by
solid-phase extraction on Oasis HLB sorbent using a 96-well
plate format. The conjugated steroids were analyzed by
UHPLC-QTOF-MSE with a single-gradient elution of
36 min (including re-equilibration time) in the negative
electrospray ionization mode. MSE analysis involved
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Introduction
Anabolic androgenic steroids (AAS) are endogenous com-
pounds that constitute the steroid profile, which is mainly
based on testosterone (T), its epimer (epitestosterone (E)), its
major metabolites (androsterone (A), etiocholanolone (Etio),
5α-androstan-3α, 17β-diol (5αAdiol) and 5β-androstan-3α,
17β-diol (5βAdiol)), and its precursor (dehydroepiandroster-
one (DHEA)) excreted as phase II glucuro- or sulfoconjugated
compounds in urine. The steroid profile provides information
on the metabolism pathway of androgenic compounds and is
essential to identify inborn errors and for the diagnosis of
diseases related to steroid secretion [1, 2]. These compounds
are widely used as doping agents in sports and are not
restricted to professionals, which becomes a public health
concern [3] because steroid administration is used for
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parallel alternating acquisitions of both low- and high-
collision energy functions. The method was validated and
applied to samples collected from a clinical study
performed with a group of healthy human volunteers
who had taken testosterone, which were compared with
samples from a placebo group. Quantitative results were
also compared to GC-MS and LC-MS/MS measurements,
and the correlations between data were found appropriate.
The acquisition of full mass spectra over the entire mass
range with QTOF mass analyzers gives promise of the
opportunity to extend the steroid profile to a higher
number of conjugated steroids.
enhancing physical appearance more than it is used for
enhancing performance.
For doping control analysis, criteria have been established
in theWorld Anti-Doping Agency (WADA) Prohibited List to
highlight the alteration of the steroid profile by exogenous
administration of T or its precursors. Indeed, intake of natural
anabolic steroids is known to raise the urinary concentration
of the parent steroid and its metabolites [4]. Therefore, some
parameters, including a testosterone over epitestosterone
ratio (T/E) greater than or equal to 4, are suspicious of
exogenous T intake and necessitates further confirmation
analysis by GC combustion isotope ratio mass spectrometry
(GC-C-IRMS) [5].
The detection of AAS by gas chromatography coupled to
mass spectrometry (GC-MS) has been extensively reported
and reviewed [1, 2, 6, 7]. GC-MS methods are sensitive and
robust, but they suffer from time-consuming sample
preparation, including hydrolysis and derivatization steps.
Moreover, this procedure does not provide complete phase
II information on the steroid profile. Thus, development
of liquid chromatography–mass spectrometry (LC-MS)
methods that allow for the direct analysis of steroid
conjugates is of great interest for studying AAS metabo-
lism. To date, the detection of intact glucuronidated and/or
sulfated steroids has been reported by LC-MS/MS [8–14].
Furthermore, ultra high-pressure liquid chromatography
(UHPLC) was recently used for metabolomics or profiling
approaches for anabolic steroids in urine [15, 16]. This
technique is of huge interest for resolving conjugated AAS,
as it allows enhancement of efficiency with columns
packed with small particles (sub-2 μm), which provide
high peak capacity within a reasonable analysis time [17].
Mass spectrometry has also improved AAS detection,
thanks to its sensitivity in detecting low amounts of
substance in complex matrices [18]. Additionally, the
improvement of time-of-flight or quadrupole time-of-flight
mass spectrometry (TOF-MS or QTOF-MS) in terms of
sensitivity and resolution has allowed its application in
doping control analysis for accurate and sensitive full mass
range acquisition [19–21]. QTOF-MS achieves accurate
mass determination on molecular and fragment ions, giving
structural information on unknown compounds or high-
lighting undiscovered metabolites [22, 23]. This technique
is therefore popular for drug metabolism studies that require
identification of new entities [24]. Moreover, QTOF-MS
coupled to a MSE acquisition provides parent and fragment
mass information in a single run, which is useful for
targeted and metabolite profiling studies [25]. Finally,
although TOF or QTOF mass analyzers could present a
limited dynamic range, some authors have reported their
use for quantitative evaluation [26–28].
In this study, the quantitative capabilities of QTOF-MS
are explored for the determination of the steroid profile. A
UHPLC-QTOF-MSE approach is presented for the simul-
taneous quantification of 11 endogenous sulfo- or glucur-
oconjugated steroids in human urine.
Experimental
Chemicals and reagents
All commercially available standards for AAS in glucuro-
and sulfoconjugated form were acquired. 4-Androsten-17β-
ol-3-one sulfate sodium salt (testosterone sulfate (TS)),
4-androsten-17α-ol-3-one sulfate sodium salt (epitestoster-
one sulfate (ES)), 5β-androstan-3α-ol-17-one sulfate sodium
salt (etiocholanolone sulfate (EtioS)), 5-androsten-3β-ol-
17-one sulfate sodium salt (dehydroepiandrosterone sulfate
(DHEAS)), 4-androsten-17β-ol-3-one glucosiduronate (tes-
tosterone glucuronide (TG)) 4-androsten-17α-ol-3-one glu-
cosiduronate (epitestosterone glucuronide (EG)), 5β-
androstan-3α-ol-17-one glucosiduronate (etiocholanolone
glucuronide (EtioG)), 5-androsten-3β-ol-17-one glucosidur-
onate (dehydroepiandrosterone glucuronide (DHEAG)), and
5α-androstan-3β, 17β-diol-3-glucosiduronate (α-diol-3-
glucuronide (5αββ-AdiolG)) were purchased from Steraloids
(Newport, RI, USA). 5α-Androstan-3α-ol-17-one sulfate
triethylammonium salt (androsterone sulfate (AS)), 5α-
androstan-3α-ol-17-one-3α-d-glucuronide (androsterone
glucuronide (AG)), [16,16,17α-2H3]androst-4-en-17α-ol-3-
one sulfate triethylammonium salt (TS-d3), [16,16,17β-
2H3]
androst-4-en-17β-ol-3-one sulfate triethylammonium salt
(ES-d3), [2,2,3β,4,4-
2H5]5β-androstan-3α-ol-17-one sulfate
triethylammonium salt (EtioS-d5), [2,2,4,4-
2H4]5α-andro-
stan-3α-ol-17-one sulfate triethylammonium salt (AS-d4),
[16,16,17α-2H3]androst-4-en-17β-ol-3-one glucuronide
(TG-d3), [16,16,17α-
2H3]androst-4-en-17α-ol-3-one glucuro-
nide (EG-d3), and [2,2,4,4-
2H4]5α-androstan-3α-ol-17-one
glucuronide (AG-d4) were purchased from the Australian
Government National Measurement Institute (Pymble,
Australia). Ultra pure water was provided by a Milli-Q system
from Millipore (Bedford, MA, USA), and ULC-MS quality of
water and acetonitrile was obtained from Biosolve (Chemie
Brunschwig, Basel, Switzerland). Formic acid and ammonium
hydroxide were purchased from Fluka (Buchs, Switzerland).
Methanol was supplied by Merck (Darmstadt, Germany).
Solutions
Stock standard solutions were obtained in methanol at a
concentration of 1 mg/mL for all standards, except for AS and
EtioS which were stocked at a concentration of 2 mg/mL.
Stock internal standards (I.S.s) solutions were obtained
in methanol at a concentration of 100 μg/mL, except for
AG-d4, which was stocked at 1 mg/mL. The working I.S.s
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solution was obtained by spiking 100 μL of the TS-d3 and
ES-d3 stock solutions; 200 μL of TG-d3, EG-d3, and AG-
d4; and 500 μL of AS-d4 and Etios-d5 into 10 mL of
methanol. Solutions were stored at −20 °C in glass tubes
fitted with PTFE caps.
Sample preparation
A solid-phase extraction (SPE) on Oasis HLB (Waters,
Milford, MA, USA) cartridges (30 mg, 30 μm particle size)
was developed for a 96-well plate format to extract
selectively glucuro- and sulfoconjugated AAS from urine
samples.
The loading solution was prepared by diluting 1 mL of
urine with 1 mL of 2% formic acid solution spiked with
10 μL of the I.S.s working solution. The extraction protocol
was performed as follows: cartridges were first conditioned
with 500 μL of methanol and equilibrated with 500 μL of a
solution containing 2% formic acid. The loading solution
was added on the sorbents, and two washing steps
followed. Cartridges were first washed with 1 mL of a
2% formic acid solution and were then washed with 1 mL
of a 5% ammonium hydroxide/methanol (90%/10%, v/v)
solution. The elution step consisted of 500 μL of 40%
methanol/60% water. Eluates were transferred into conical
glass tubes, and the wells were washed three times with
500 μL of methanol. The solvent was evaporated to dryness
under a gentle air stream, and the dry residue was recon-
stituted with 100 μL of a mixture of 30% acetonitrile/70%
water.
UHPLC conditions
Separations were performed on an Acquity UPLC system
(Waters) with Acquity UPLC columns (BEH C18 150×
2.1 mm, 1.7 μm) at 25 °C and 300 μL/min. A Van Guard
(Waters) pre-column (BEH C18, 5×2.1 mm, 1.7 μm) was
placed prior to the column. The mobile phase was (A) 0.1%
formic acid in water and (B) 0.1% formic acid in
acetonitrile. The gradient started linearly from 5% to 37%
B over 25 min, followed by a washing step to 95% B for
3 min; the system was then re-equilibrated for 8 min. The
injection volume was fixed at 20 μL in the full loop mode,
and samples were maintained at 4 °C in the autosampler.
QTOF-MSE parameters
Analyses were performed using a Micromass-Q-Tof Premier
mass spectrometer (Waters) equipped with an electrospray
ionization (ESI) source operated in the negative mode. MS
operating conditions were set as follows: the desolvation gas
flow was 800 L/h with a temperature of 360 °C, the capillary
voltage was defined as 2.4 kV, and the cone voltage was kept
constant at 50 V. The micro-channel plates (MCPs) were
operated at 1,750 V with 3.6 GHz time-to-digital converters
(TDC), the source temperature was 120 °C, and the cone gas
flow and the collision gas flow were set to 10 L/h and
0.25 mL/min, respectively.
The QTOF mass spectrometer was operated in wide-pass
quadrupole mode with a low collision energy set at 5 eV in
the first function, and a collision energy ramp from 5 to
70 eV was applied in the second function (MSE mode).
Data were collected in V-optics centroid mode over ranges
of m/z 95–1,000 in the first function and m/z 50–1,000 in
the second function with a scan time of 0.2 s and an
interscan delay of 0.02 s. For the dynamic range enhancement
(DRE) lockmass, a 2-ng/mL solution of leucine-enkephalin
(Sigma-Aldrich, Buchs, Switzerland) was infused through the
Lock Spray probe at 5 μL/min.
Software
Data acquisition, data handling, and instrument control
were performed using MassLynx Software (Waters).
Validation
Guidelines
Experiments were conducted in compliance with the
Internal Standards for Laboratories (ISL) of the World
Anti-Doping Code [29]. Detailed procedures were found in
the “Identification method validation” section from the
International Conference for Harmonization (ICH) guide-
lines [30]. The US Food and Drug Administration (FDA)
guidelines [31] and the Third American Association of
Pharmaceutical Scientists (AAPS)/FDA Bioanalytical
Workshop in 2006 [32] were consulted for the assay of
stability and carry-over, respectively. Finally, the last
concept paper regarding bioanalysis from the European
Medicines Agency (EMEA) [33] was referred for the
requirement of matrix effect study in case of LC-MS
methods.
Selectivity
Because human urine samples may contain endogenous
AAS, negative urine samples from children younger than
3 years old (one urine sample from a boy and two urine
samples from girls) were collected for development and
validation purpose because they contained a lower amount
of steroids [34]. The levels of endogenous steroids (5αββ-
AdiolG, TG, EG, DHEAG, AG, EtioG, TS, ES, DHEAS,
AS, and EtioS) were estimated with the negative children's
urine samples and were considered sufficiently low to be
used for calibration and validation procedures (data not
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shown). UHPLC-QTOF-MSE chromatograms were visually
examined and compared for potential interferences with the
negative urine samples. The negative urine samples were
also spiked with the working I.S.s solution to ensure the
lack of selectivity towards the I.S.s themselves.
Matrix effects
Matrix effects were determined using a method described by
Matuszewski et al. [35] and revisited by Marchi et al. [36].
Assays were performed at low and high concentrations for
each compound (5 and 200 ng/mL for 5αββ-AdiolG; 2 and
100 ng/mL for TS and ES; 10 and 200 ng/mL for TG, EG,
and DHEAG; 500 and 2,000 ng/mL for DHEAS, AS, and
EtioS; and 1,000 and 4,000 ng/mL for AG and EtioG). Four
samples were prepared for the exhaustive classification of
phenomena that estimated the global process efficiency (PE),
the matrix influence on the MS signal (ME; including
ionization perturbation), the extraction recovery (RE), and
the extraction yield (EY). Indeed, PE was expressed as a
percentage of the peak areas of the analytes spiked in the
matrix to the areas of the analytes in a neat solution. The ME
was evaluated by comparing the peak areas of the standards
spiked in the extracted urine to that of the neat standard
solution. The RE was obtained by calculating the ratio of the
peak areas of the analytes spiked in the urine to the analytes
reconstituted in a post-extracted matrix. Finally, the EY was
expressed as the ratio of the peak areas of the standard
extracted in water to that of the neat solution.
Quantitative analysis
Validation was conducted over three consecutive series.
Calibration standards were prepared at four levels (k=4),
and validation standards were prepared at five levels (k=5);
each were performed in triplicate (n=3). Due to the high
excretion of some steroids in urine, a dilution factor of 10
was tested among the validation standards for DHEAS, AS,
EtioS, AG, and EtioG. Calibration curves were built based
on the peak area ratios of 5αββ-AdiolG, TG, and DHEAG
to TG-d3; EG to EG-d3; AG and EtioG to AG-d4; TS to
TS-d3; ES and DHEAS to ES-d3; AS to AS-d4; and EtioS to
EtioS-d5. The curves were generated over the ranges from 1
to 200 ng/mL for TS and ES; from 5 to 500 ng/mL for TG,
EG, and DHEAG; from 1 to 500 ng/mL for 5αββ-AdiolG;
from 50 to 3,000 ng/mL for DHEAS, AS, and EtioS; and
from 500 to 8,000 ng/mL for AG and EtioG.
Results were expressed in terms of trueness, repeatability,
and intermediate precision at each concentration level
and were depicted in tolerance profiles for each compound
[37, 38].
Trueness was defined as the relative bias and was
expressed as a percentage of the average recalculated
concentrations at each level. Repeatability was considered
as the relative standard deviation (RSD) of the averaged
intra-day standard deviation to the theoretical value.
Finally, intermediate precision was expressed as the RSD
of the inter-day standard deviation to the theoretical value.
An external standard calibration with four levels of
concentration was used in triplicate to quantify the
metabolites in the real-case urine samples.
Carry-over
The carry-over effect was estimated by injecting an extracted
spiked sample at its highest level of concentration (highest
calibration standard) for each analyte, followed by three
consecutive blank water samples. Peak areas in the extracted
samples were considered as 100%, and if a peak was found at
the expected retention time in the blank samples, it was
expressed as a percentage of the previous sample peak area.
Stability
Stability of analytes was evaluated by following the EMEA
concept paper [33] with four different samples. Samples
were either maintained at +4 °C or at batch temperature (ca.
+22 °C), or they were subjected to three freeze (−20 °C)
and thaw (ambient temperature) cycles before analysis,
respectively. Finally, an additional sample was prepared for
the evaluation of long-term stability at +4 °C. The time
between each analysis was 48 h, except for the long-term
stability assay, which was measured after 1 month.
Application to clinical study
Urine samples from a clinical study conducted in 2006 at the
Swiss Laboratory for Doping Analyses were analyzed with
the method described herein. The clinical study consisted of
the oral intake of 12 placebo and 19-norandrostenedione or
testosterone undecanoate pills [39]. The pills were composed
of 300 mg of mannitol for the placebo group, 80 mg of
testosterone undecanoate and 115 mg of mannitol in the
testosterone group, and 100 mg of 19-nor-4-androstenedione
and 127 mg of mannitol in the 19-norandrostenedione group.
The protocol of the study was set as described in Table 1,
such that pill intakes occurred three times a week and urine
spots were collected in accordance with the study design.
Urine samples were split into 20-mL flasks and stored
at −20 °C. For this research, selected samples of both the
placebo (n=7) and testosterone (n=8) intake groups were
investigated. Amongst the urine specimens, five kinds of
samples were studied. However, a t00 sample was deter-
mined with the urine collected before any pill intake
occurred. Additionally, samples t01 to t05 were taken at 0,
4, 8, 24, and 200 h after pill intake, respectively. Samples
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were defrosted at ambient temperature and analyzed. Because
the clinical study samples were stocked for 4 years at −20 °C,
five of them were re-analyzed with the GC-MS accredited
method (STS 288) to ensure that their stability and validity
had been preserved over the intervening years. No significant
differences between the measured values for all of the analytes
were observed. For the purpose of this study, samples were
analyzed by UHPLC-QTOF-MSE in triplicate, and the
analytes were quantified with an external calibration curve.
Steroid concentrations were corrected using specific gravity,
as was recommended in the WADA technical document [5].
Samples were randomized to avoid batch effect, and a
calibration curve was analyzed at the beginning of the
sample list and in the middle, to consider the susceptible loss
of sensitivity during the batch. One batch constituted 15
samples after triplicate studies and, in addition, a calibration
curve of four levels (57 samples) was determined.
Results and discussion
Method development
AAS
The steroid profile includes the measurement of glucuro-
and sulfoconjugated T, E, A, Etio, 5α-Adiol, and 5β-Adiol,
whose structures are presented in Fig. 1. In regards to the
reference population concentration ranges, high sensitivity is
required for some of the analytes, such as TG, EG, TS, ES,
and DHEAG, because they are normally excreted in low
amounts (0.5 to 40 ng/mL) in urine. Notably, the only
available standard for the 5α- and 5β-Adiol was the isomer
5αββ-AdiolG, which was a minor metabolite and was
excreted in low concentrations (0.5 to 10 ng/mL). On the
other hand, some analytes are highly excreted in urine, with
concentrations reaching 8,000 ng/mL (AG, EtioG, DHEAS,
AS, and EtioS) [4, 7, 11]. Therefore, an analytical method
able to extract sulfated and glucuronidated steroids together
with selective chromatographic separation to resolve isomers
was mandatory.
Sample preparation
A SPE procedure was developed for conjugated AAS, as it
allowed for superior sample clean-up and analyte pre-
concentration. Oasis HLB cartridges of 30 mg were used to
extract simultaneously the sulfated and glucuronidated
steroids from the 96-well plate with high sample capacity.
A 1-mL volume of the urine specimen was then loaded
onto the cartridges with 1 mL of 2% formic acid, which
ensured constant pH. Two washing steps were successively
performed. The first was performed in acidic conditions
(2% formic acid), and the second was performed with a
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Fig. 1 Structures of the investi-
gated compounds. At the right
side of the picture, phase II
metabolism enzymes were
presented. Uridine diphosphate-
glucuronosyltransferase (UGT)
for glucuronide conjugation and
sulfotransferase (SULT) for
sulfate conjugation mechanism
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Table 1 Design of the clinical study. Pill administrations were performed during the four first weeks. Spot urine samples were collected during
the first week, during the second week, on day 24 during the third week and finally on the last day of the study
Week 1 2 3 4 5 6
Pill intake/week 3 3 3 3 - -
Urine spot First day Every day Day 24, 4 spots Last day
Sample code t00 t01→ t04 t05
basic solution containing organic solvent (5% ammonium
hydroxide in methanol, 90%/10%, v/v). The proportion of
methanol was evaluated to avoid the elution of the analytes
and was set at a 10% maximum. Various conditions were
also tested for the elution, from 30% to 95% methanol.
Elution with 40% methanol was selected, as it allowed the
complete recovery of the analytes excreted at low concen-
tration and adjusted the extracted amount for the com-
pounds found at high concentrations in urine, such as
DHEAS, which could saturate the QTOF detector equipped
with TDC cards. Finally, a preconcentration factor of 10
was obtained, which was necessary to detect and quantify
the lowest excreted endogenous AAS. Extraction recoveries
(RE) were between 78% and 137% for the compounds
excreted at low concentrations and between 74% and 120%
for the high-concentration compounds, as presented in
Table 2. Notably, the REs higher than 100% were attributed
to a salting-out effect that could increase the amount
extracted in the urine, compared to water, due to the
presence of salts, fatty acids, amino acids, or organic bases
in urine matrix. As an exception, DHEAS was extracted
with REs of 42% and 49% at low and high concentrations,
respectively. However, as this analyte was observed at a
high amount in urine, its detection was not altered. Overall,
this method allowed for the simultaneous extraction of the
sulfated and glucuronidated steroid from the urine matrix
with satisfactory RE.
UHPLC
Initial UHPLC conditions Various column chemistries,
mobile phase compositions, and temperatures were
evaluated to obtain the highest possible selectivity
between analytes, especially between the different pairs
of isomers (TG/EG, TS/ES, AG/EtioG, and AS/EtioS),
not resolved by MS. For the stationary phase chemistry
screening, specific short columns (50×2.1 mm, 1.7 μm)
of various reversed phase chemistries (e.g., C18, phenyl,
and C18 shield) were selected to evaluate the selectivity
in a minimum period of time. Two different mobile
phase additives, ammonium formate buffer (20 mM at
pH 3.0) and 0.1% formic acid, were tested. Finally, the
column temperature was maintained either at 30 °C or
50 °C to assess the influence of this parameter on the
selectivity.
However, due to the difficult separation of the isomers,
additional combinations of column chemistries, mobile
phase additives, and temperatures were tested. To limit the
number of conducted experiments, only two gradients (5%
to 70% acetonitrile in 8.6 and 26 min) were performed, and
the retention times were computed on modeling software
(Osiris v.4.2, Datalys, Grenoble, France). By modeling the
behavior of each compound, the software highlighted the
best separation that can be attained with a given condition.
For steroids, the best separation of critical pairs of isomers
(AS/EtioS and AG/EtioG) was obtained with the Acquity
BEH C18 column at a temperature of 50 °C and with 0.1%
formic acid added to the mobile phase. Nevertheless, the
resolution between the most critical pair of isomers, AS and
EtioS, was still not sufficient (Rs equal to 0.6) and
endogenous interferences from the urine co-eluted with
DHEAG, in particular. Therefore, final conditions were
performed on a 150-mm column length to ensure enough
selectivity for the quantitative measurement of DHEAG in
urine.
Separation optimization To start, an isocratic step was
performed with 27% acetonitrile, and three different
Table 2 Process efficiency, matrix effect, extraction recovery, and extraction yield for the investigated analytes at low and high concentration
Low conc. High conc. Low concentration High concentration
[ng/mL] [ng/mL] PE (%) ME (%) RE (%) EY (%) PE (%) ME (%) RE (%) EY (%)
αββ-AdiolG 5 200 82 80 103 98 105 92 114 110
TG 10 200 127 98 130 110 108 91 96 86
EG 10 200 136 80 137 110 120 105 114 109
DHEAG 10 200 67 86 78 96 89 95 94 99
AG 1,000 4,000 111 90 124 92 101 98 103 83
EtioG 1,000 4,000 109 80 136 97 126 104 120 100
TS 2 100 122 86 90 67 126 107 118 53
ES 2 100 101 107 94 106 90 100 90 91
DHEAS 500 2,000 43 102 42 58 70 111 49 74
AS 500 2,000 84 95 89 98 75 102 74 83
EtioS 500 2,000 90 91 99 101 75 91 82 83
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constituents were detected under the peak of DHEAG
when extracting the trace at m/z 463.2332±0.0500 Da,
corresponding to the theoretical exact mass of deprotonated
DHEAG. Here, HPLC modeling software was employed,
and the best separation was obtained at 30 °C with a
gradient of 5% to 37% acetonitrile over 25 min and at a
flow rate of 300 μL/min, as shown in Fig. 2a for the
extracted ion DHEAG at m/z 463.23±0.05 Da. However,
higher chromatographic resolution was still mandatory for
separation between DHEAG and an unknown endogenous
compound #1. In this case, the impact of a lower column
temperature was evaluated in a univariate way, and the
corresponding chromatograms are presented in Fig. 2b, c. A
sufficient separation for all of the analytes was finally
obtained at 25 °C. Indeed, when the column was main-
tained at 30 °C, compound #1 was co-eluting with
DHEAG, whereas at 20 °C, the peak of the analyte #2
interfered with DHEAG. The three unknown peaks were
most probably isomers of DHEAG.
To summarize, the best conditions to separate the
investigated analytes with sufficient selectivity and reason-
able analysis time (36 min) was finally achieved on an
Acquity BEH C18 (150×2.1 mm, 1.7 μm) column, at a
temperature of 25 °C, using a gradient from 5% to 37%
acetonitrile in 25 min, and at a flow rate of 300 μL/min.
QTOF-MSE
Both ESI-positive and ESI-negative modes were tested for
the ionization of sulfated and glucuronidated steroids. As
expected, the highest sensitivity was obtained by analyzing
the conjugated steroids as their deprotonated form [M−H]−
in the negative ESI mode. Specifically, the selectivity
obtained by the coupling of the UHPLC to the QTOF-MS
is represented in Fig. 3. Here, two chromatograms were
extracted from the same analysis to show separately the
sulfoconjugated (Fig. 3a) and glucuroconjugated (Fig. 3b)
steroids. Notably, the compounds were resolved either by
MS or by UHPLC regarding steroid isomers.
For the MS acquisition mode illustrated in Fig. 4a and b
for sulfoconjugated and glucuroconjugated DHEA, respec-
tively, MSE was selected. It consisted of a first function that
was obtained in wide-pass quadrupole mode at a low fixed
collision energy (5 eV) and an alternated second function
with ramped collision energy from 5 to 70 eV. This mode
was achieved to obtain maximum information in a single
run, with no pre-selection of a precursor ion in the
quadrupole.
Specifically, by using ramped collision energy, the depro-
tonated molecule was maintained, together with the generated
fragments. Moreover, as discussed elsewhere [11], the
sulfoconjugated steroids had a low fragmentation pattern.
The unique ion formed by applying collision energy on the
sulfoconjugated steroid was the sulfate moiety itself at
m/z 96.96 (HSO4
−; Fig. 4a). The ramped collision energy
also yielded more information regarding the fragmentation of
glucuroconjugates (Fig. 4b), but they were not specific, as
fragments were generated principally from the glucuronic
acid itself [13]. For example, the fragment at m/z 287.20,
corresponding to the free steroid (neutral loss of glucuronic
acid, m/z 176.03), was found at less than 10% of the base
peak, whereas several fragments of glucuronic acid were
also observed (m/z 157.02, m/z 113.02, m/z 85.03, and
m/z 75.01). The parent and fragment ions obtained for
sulfated and glucuronidated steroids are listed in Table 3.
The MSE mode was used as an example to gather more
information about unknown peaks #1, #2, and #3; the MSE
Time 
[min]
%
0
100 Intensity 3.26e4# 1
# 3 
DHEAG
# 2
a
TG tR 11.26
# 1 tR 13.05
DHEAG tR 13.26
# 2 tR 13.57
# 3 tR 13.97
EG tR 16.56
%
0
100 Intensity 2.61e4# 1
# 2 # 3 
DHEAG
b
TG tR 11.51
# 1 tR 13.29
DHEAG tR 13.57
# 2 tR 13.82
# 3 tR 14.21
EG tR 16.88
Time 
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12.00 14.00
12.00 14.00
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%
0
100 Intensity 2.92e4# 1
# 2 # 3 
DHEAG
c
TG tR 11.87
# 1 tR 13.62
DHEAG tR 14.02
# 2 tR 14.23
# 3 tR 14.59
EG tR 17.30
Time 
[min]
Fig. 2 Extracted ion chromatogram (XIC) at m/z 463.23±0.05 Da in
urine matrix. Chromatographic separation at 300 μL/min with a
gradient from 5% to 37% acetonitrile over 25 min at a 30 °C, b 25 °C,
and c 20 °C. Peaks #1, #2, and #3 were endogenous isomers of
DHEAG
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spectra are shown in Fig. 5a–d for each peak. The spectra
contained characteristic fragments of DHEAG together with
parent and product ions from the co-eluting peaks.
However, without selecting a precursor ion, co-eluting peak
fragments obtained in the spectra were also viewed. In these
cases, we linked a precursor ion to its product ions by use of
retention time information and known mass defect (glucuro-
nide, sulfate, or water loss). Another way to determine this
relationship between the ions could also be automatically
establish by a dedicated software. As observed in Fig. 5a, ions
corresponding to peak #1 were the parent ion at m/z 463.23
and fragment ions at m/z 287.20, m/z 157.02, m/z 113.02,
m/z 85.03, and m/z 75.01. These ions are common to a
glucuronide conjugate, as reported in Table 3. However,
interfering ions at m/z 367.15 and 96.96, corresponding to a
sulfoconjugated steroid and to the inorganic hydrogenosul-
fate (HSO4
−), respectively, were also present in the spectrum,
due to nonselective fragmentation. For further confirmations,
MS/MS experiments were conducted on each peak with
selection of the parent ion (m/z 463.23) as the precursor ion
for fragmentation at a fixed collision energy of 25 eV (data
not shown). The same fragments were obtained with MS/MS
and MSE acquisition modes by selecting either the m/z
463.23 precursor ion or by applying the nonselective ramped
collision energy. The advantages of MSE over MS/MS
acquisition mode were the nonselective approach allowing
detection and characterization of new entities in metabolite
studies, as all data were collected in exact mass mode.
Moreover, the information provided by the QTOF-MSE
acquisition was particularly relevant for biological matrices,
as data could be processed retroactively.
Validation of the study
Selectivity
An additional experiment was previously performed to
improve resolution by injecting the analytes extracted
in the matrix on a 300-mm column length. Here, two
150-mm columns were connected in series, and the
optimized method was transferred geometrically by
adjusting the injection volume (40 μL) and the gradient
profile (5% to 37% acetonitrile in 83.9 min). Further-
more, the flow rate was reduced (180 μL/min) to reach
a backpressure compatible with the system. Overall, no
interfering peaks were observed in the extracted MS
traces for all analytes.
As the investigated analytes are endogenous com-
pounds, selectivity was evaluated by the quantitative
analysis of six independent adult urine samples, and the
results were compared to the GC-MS accredited method
measurements. For the 11 analytes, the results obtained
were not significantly different than those obtained by
GC-MS, suggesting no over- or underestimation. More-
over, the MSE acquisition mode allowed for the enhance-
ment of the selectivity. Specifically, the combined
information of the molecular ion with the fragmentation
pattern obtained in the second function allowed for
specific confirmation ions. The selectivity was also
estimated by comparing I.S.s spiked in negative children's
urine specimens to adult urine specimens. For each I.S., no
co-elution was observed at the selected retention time and
m/z window.
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Fig. 3 UHPLC-QTOF-MS
chromatogram (Acquity BEH C18
150×2.1 mm; 1.7 μm) of the
investigated analytes. For better
readability, the chromatogram
was presented in two parts.
a The traces corresponded to
sulfoconjugated steroids were
extracted at m/z 367.16±0.05 Da
and 369.17±0.05 Da. b The
traces from glucuroconjugated
steroids were extracted in the
chromatogram at m/z 467.26±
0.05 Da, 463.23±0.05 Da, and
465.24±0.05 Da
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Matrix effects
The ME were measured on the basis of experiments
described by Matuszewski et al. [35] and classified
according to the method described by Marchi et al. [36]
in case of SPE prior to LC-MS. The measured PE, ME, RE,
and EY, at low and high concentrations, are presented in
Table 2. PE was considered suitable for quantitative
analysis, and ME reflected no ion suppression or enhance-
ment effect with values between 80% and 111% at low and
high concentrations. Additionally, REs were satisfactory for
all of the analytes, as a salting-out effect, due to the
presence of the matrix, enhanced the detection of most
analytes at low concentrations, except for DHEAS, which
was extracted with less than 50% at both concentrations.
However, as discussed before, this compound was excreted
at a high concentration, so that the loss during the
extraction step was not detrimental to its sensitivity. Lastly,
EY was good, with values near 100% for all analytes
except for TS and DHEAS. For these compounds, EY was
lower than 70% and 80%, respectively, but it was
considered sufficient to detect them at low concentrations.
Quantitative analysis
Results of the validation assays were built into a tolerance
profile for each compound with a β-value of 80%, as shown
in Fig. 6, and the investigated parameters are reported in
Table 4. As recommended elsewhere [31], a variability of
30% was found to be acceptable for the quantification of
Function 1: MS 5eV
Molecular ion
Molecular ion and fragments
Function 2: MSE 5 to70eV
XIC 463.23 0.05
Time
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464.2414
m/z
60 100 140 180 220 260 300 340 380 420 460
%
0
100 Intensity 2.01e3 463.2359
113.0294
96.9695
85.0339
75.0180
71.0212
413.2054
175.0233
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Fig. 4 UHPLC-QTOF-MSE
acquisition mode. a In the
first function obtained at low
collision energy (5 eV), the
molecular ion of DHEAS is
shown at m/z 367.16, while the
sulfate moiety fragment at m/z
96.96, together with the
molecular ion, is obtained in the
second function with ramped
energy from 5 to 70 eV.
b Spectra at low and ramped
energy were obtained from the
peak trace of DHEAG. The
molecular ion was found in the
first function at m/z 463.23. A
fragmentation pattern was
obtained in the second function
with ions at m/z 287.20, m/z
157.01, m/z 113.02, m/z 85.03,
m/z 75.01, and m/z 71.02,
together with the molecular
ion at m/z 463.23
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these steroids in urine. Additionally, for the calibration, a linear
regression was obtained after 1/x-weighting for each analyte.
Trueness, repeatability, and intermediate precision were
found to be acceptable over the validated range for the
majority of compounds, as shown in Table 4. However,
the lower limit of quantification was estimated from the
absolute tolerance profile at 2, 4, and 5 ng/mL for TS, ES,
and 5αββ-AdiolG, respectively, instead of 1 ng/mL, as
m/z 
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Fig. 5 MSE spectra of a peak #1 (tR, 13.29), b DHEAG (tR, 13.57), c peak #2 (tR, 13.82), and d peak #3 (tR, 14.21) obtained in the second
function with ramped energy from 5 to 70 eV
Table 3 Parent and fragment ion assignment for glucuronidated and sulfated phase II metabolites of testosterone
Compounds Deprotonated molecule m/z Fragments m/z
Sulfated steroids AS, EtioS [M−H]− 369.17 [HSo4]− 96.96
TS, ES, DHEAS [M−H]− 367.16
Glucuronidated steroids AG, EtioG [M−H]− 465.24 [M–H–H2O]− 447.23
[M–H–Gluc]− 289.20
αββ-AdiolG [M−H]− 467.26 [M–H–H2O]− 449.25
[M–H–Gluc]− 291.21
TG, EG, DHEAG [M−H]− 463.23 [M–H–H2O]− 445.22
[M–H–Gluc]− 287.20
Common fragmentation to all glucuonides [Gluc–H]− 175.02
[Gluc–H–H2O]
− 157.01
[Gluc–H–H2O–CO2]
− 113.02
[Glu–?]− 85.03
[Glu–?]− 75.01
[Glu–?]− 71.02
512 F. Badoud et al.
the repeatability and intermediate precision were above
30%. The tenfold dilution factor for the four analytes
excreted in urine at high amounts (AS, EtioS, AG, and
EtioG) was also validated. However, it is notable that, at
the lower limit of quantification (LLOQ), the number of
points per peak was estimated at a minimum of 30,
which was sufficient for the quantitative analysis,
because it took into account the MSE-ramped collision
energy function and the DRE lockmass function. The
method was thus considered adequate for the determina-
tion of endogenous sulfated and glucuronidated steroids in
urine.
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Table 4 Validation parameters for the 11 investigated steroids
Compounds Concentrations [ng/mL] Trueness (%) Repeatability (%) Intermediate precision (%) LLOQ [ng/mL] LOD [ng/mL]
TS 1 97 28.4 47.6 2 1.0
2 102 17.1 17.8
10 96 8.3 13.1
100 104 11.4 12.1
200 109 4.2 8.9
ES 1 100 17.8 29.8 4 1.0
2 116 21.4 22.7
10 101 8.9 10.5
100 102 3.6 6.8
200 92 9.1 10.7
DHEAS 50 97 13.3 13.1 50 1.0
500 102 7.5 7.6
1,000 97 8.5 11.6
3,000 93 8.0 12.2
30,000/10 119 17.8 17.5
AS 50 108 20.9 21.6 50 1.0
500 106 4.1 7.7
1,000 104 9.8 15.0
3,000 93 7.6 13.1
30,000/10 91 5.9 12.8
EtioS 50 108 9.1 10.2 50 1.0
500 93 7.6 11.6
1,000 89 5.0 7.3
3,000 99 17.7 18.3
30,000/10 88 4.5 10.3
αββ-AdiolG 1 125 70.1 76.0 5 1.0
5 102 9.9 8.5
50 96 6.3 7.3
100 110 8.4 8.0
500 102 12.9 12.0
TG 5 86 16.3 18.9 5 1.0
10 100 13.3 14.1
50 102 10.6 13.2
100 99 16.1 15.9
500 97 3.8 11.9
EG 5 93 15.1 16.3 5 1.0
10 104 7.8 13.8
50 110 4.1 7.0
100 108 3.8 8.4
500 111 10.7 11.7
DHEAG 5 109 14.7 16.9 5 1.0
10 100 9.0 11.6
50 106 10.3 11.8
100 103 7.6 10.2
500 97 12.5 14.4
AG 500 100 10.1 10.5 500 5
2,000 105 5.4 10.0
4,000 101 8.0 10.6
8,000 95 7.6 15.3
Carry-over
The carry-over effect at the injection step was determined
by analyzing a water blank sample directly after the highest
level standard calibration. No peak was found in the
subsequent blank samples, except for EtioG and AG, for
which only 0.02% and 0.01%, respectively, of the former
peak was detected in the first blank sample. In other words,
the carry-over effect was found to be negligible for all
analytes.
Stability
Stability assays were performed at a concentration of
5 ng/mL for TS and ES; at 10 ng/mL for 5αββ-AdiolG,
TG, EG, and DHEAG; at 200 ng/mL for AS, EtioS, and
DHEAS; and at 1,000 ng/mL for EtioG and AG. Stability
was evaluated on three measurements separated by 48 h in
three storage conditions as follows: at +4 °C (autosampler
condition), at room temperature (+22 °C), and after three
freeze–thaw cycles (freezing at −20 °C and thawing at
room temperature). All of these conditions did not affect the
stability of the analytes with relative standard deviations
(RSD) below 15% (data not shown). However, after
maintaining the analytes at +4 °C for 1 month in the
matrix, sample degradation was observed with RSD rising
to 27% for DHEAG. Analytes loss was estimated to be
around 30% of the initial peak area. Consequently, samples
shall not be conserved more than 6 days (three times 48 h)
before analysis at +22 °C or +4 °C.
Application to clinical study
The 100 samples from a clinical study were analyzed to
determine the levels of glucuronidated and sulfated steroids.
UHPLC-QTOF-MS results were compared with values
obtained by GC-MS for the glucuroconjugates and by LC-
MS/MS for the sulfoconjugates, with a method presented
elsewhere [11]. The Bland–Altman approach was used to
further assess the differences between the methods. Quanti-
tative measurements obtained by UHPLC-QTOF-MS were
in agreement with those performed by GC-MS and LC-MS/
MS, as the statistical Bland–Altman test showed no
significant difference with a risk α of 0.05.
All well-known parameters influenced by testosterone
administration were modified, in terms of ratio or individual
levels, as already described by Baume et al. [40]. For the
majority of subjects (n=6), an enhancement of the T/E value,
together with TG, AG, and EtioG concentrations, was
observed from point +4 h (t02) to point +8 h (t03) after
testosterone administration. However, for two subjects
among the eight who had taken 80 mg of testosterone, no
particular change in concentration or ratio was observed.
One athlete was detected to have a deficient genotype in
the UGT2B17 gene, causing significantly lower excretion
of TG in urine [41], and the other was considered as a fast
excretor, with an excretion peak and return to basal state
before t02. Overall, the detection window based on
glucuronidated steroids was short and not very sensitive,
as two individuals out of eight were not detected. The first
hypothesis was to observe sulfated metabolites by consid-
ering the fact that if a deletion was present on the
glucuroconjugation enzyme, sulfoconjugation could com-
pensate for steroid elimination. However, the concentra-
tion of the inorganic sulfate substrate for the enzyme
sulfate transferase could be the limiting factor [42], and
further investigation should be performed on sulfoconju-
gated metabolism.
As analyses were acquired in the QTOF-MSE mode, rich
information was provided by combining exact mass
measurements over the mass. This opened the way to a
broader steroid profile with chemometric tools for data
treatment to highlight minor metabolites or new steroid
entities influenced by an oral intake of testosterone.
Conclusion
Direct analysis of steroid metabolism comprising phase II
metabolites is still challenging because these compounds
are not restricted to professional sport and can be used as
biomarkers of diseases related to steroid secretion.
A UHPLC-QTOF-MSE method was validated and
allowed for the quantification of glucuronidated and
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Table 4 (continued)
Compounds Concentrations [ng/mL] Trueness (%) Repeatability (%) Intermediate precision (%) LLOQ [ng/mL] LOD [ng/mL]
80,000/10 98 4.1 4.6
EtioG 500 99 17.5 21.2 500 5
2,000 105 4.8 5.4
4,000 100 13.8 13.4
8,000 105 11.9 13.7
80,000/10 95 7.2 10.5
sulfated steroids within the same analysis. Thanks to
UHPLC resolution, critical pairs of isomers can be
separated. The sample preparation was performed on Oasis
HLB SPE cartridges and allowed for a superior sample
clean-up and ten-fold pre-concentration of analytes. The
chromatographic analysis time required to separate targeted
analytes was 36 min (including the re-equilibration time) on a
150-mm column length. An optimal gradient time was
mandatory to obtain the needed selectivity between the
investigated analytes and the potentially interfering com-
pounds present in the matrix. Indeed, as the sample
preparation was generic towards the class of conjugated
steroids present in the urine, numerous steroid phase II
metabolites were extracted with the targeted compounds.
However, these compounds can also be used as biomarkers of
steroid administration within the framework of a clinical
study. By combining information obtained with QTOF-MSE
acquisition mode and with chemometric tools, additional
perspectives on this work could be expected. Furthermore,
this method opens a promising route to a broader under-
standing of steroid profile (steroidomics), including sulfo-
conjugated metabolites, and to the discovery of potentially
important indirect biomarkers for the detection of exogenous
testosterone misuse, which will be published elsewhere.
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